FDA Releases COVID-19 Test Performance Data
IVDs from PerkinElmer and Viracor Eurofins were the most sensitive, agency says
The data compares the sensitivity of almost 200 diagnostics against a standardized set of samples.
You may also be interested in...
A review by a government watchdog found the FDA’s review process for COVID-19 diagnostics was plagued by issues including allowing low-quality tests to slip through, high reviewer workloads, and manufacturer frustration.
The US agency on 29 May gave two additional tools to COVID-19 test developers: an emergency use authorization template for tests using at-home sample collection kits, and a reference panel for the disease.
The government collected $2.68bn from settled False Claims Act cases last year, the US Department of Justice said. Another 12 device-related cases were announced in February alone.